MSB 3.21% $1.13 mesoblast limited

Gilead vs Mesoblast, page-11

  1. 468 Posts.
    lightbulb Created with Sketch. 888
    the trial was enrolling patients at multiple hospitals. I am afraid your analysis is wrong.

    Gilead said a few days ago:
    ”Earlier this week we heard Over 18 days, 68% of the patients improved, with 17 of the 30 patients on mechanical ventilation being able to get off the breathing device. Almost half of the patients studied were ultimately discharged, while 13% died. Mortality was highest among those who were on a ventilator, with 18% of them dying.”
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.